Extraordinary General Meeting of Diamyd Medical AB Cancelled

  Extraordinary General Meeting of Diamyd Medical AB Cancelled

Business Wire

STOCKHOLM -- February 27, 2013

Regulatory News:

The Extraordinary General Meeting of Diamyd Medical AB (STO:DIAM-B)(Pink
Sheets:DMYDY) summoned to for March 13, 2013 is cancelled.

The group of shareholders who had previously requested an Extraordinary
General Meeting of Diamyd Medical AB has formally withdrawn their request. The
Extraordinary General Meeting summoned to for March 13, 2013 is therefore
cancelled.

About Diamyd Medical

Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project consists of the protein GAD for the
treatment and prevention of autoimmune diabetes. Two Swedish
researcher-initiated Phase II studies are ongoing. One study evaluates whether
GAD can prevent type 1 diabetes in children who are at high risk of developing
the disease and one study evaluates whether GAD in combination with relatively
high doses of vitamin D and ibuprofen can preserve the body's own ability to
control the blood sugar level in children and adolescents newly diagnosed with
type 1 diabetes.

Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.

Diamyd Medical AB (publ)

Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46
8 661 63 68 E-mail: info@diamyd.com. Reg. no: 556530-1420

This information was brought to you by Cision http://news.cision.com

Contact:

Peter Zerhouni
President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26
E-mail: press@diamyd.com
 
Press spacebar to pause and continue. Press esc to stop.